

THOMAS L. PETTY
ASPEN LUNG CONFERENCE

68th Annual Meeting

“Pulmonary Vascular Disease: The Vascular Niche and Its
Interactions in Lung Homeostasis and Disease”

June 9-12, 2026

Monday, June 8, 2026 -- Evening

5:00-7:00 PM Evening Registration

Gant Conference Center

Tuesday, June 9, 2026 – Morning

7:45-7:55 AM Welcome/Introduction

Tim Lahm, M.D., Co-Chair
Eva Nozik, M.D., Co-Chair
Yen-Rei Andrea Yu, M.D., Ph.D., Co-Chair

7:55-8:20 AM **Patient Experience: Resilience and Recovery in Pulmonary Hypertension**

Eric Borstein/Los Angeles, CA

8:20-8:30 AM **The Thomas L. Petty Aspen Lung Conference: A Historical Perspective**

Dennis E. Doherty, M.D., FCCP

Professor of Medicine/University of Kentucky

Secretary/Treasurer, National Lung Health Education Program

Theme 1: Novel Insights in Pulmonary Hypertension Phenotypes and Vascular Remodeling in

Pulmonary Circulation-Moderators: Todd Bull, M.D., Sandeep Sahay, M.D., Tatiana Kurdoshova, M.D.

8:30-9:05 AM

THOMAS L. PETTY LECTURE

**“NOVEL PULMONARY HYPERTENSION PHENOTYPES AND
MECHANISMS OF VASCULAR REMODELING”**

Anna R. Hemnes, M.D.

Professor and Elsa S. Hanigan Chair in Medicine

Director, Division of Allergy, Pulmonary and Critical Care Medicine

Director, Center for Lung Research

Vanderbilt University Medical Center

Nashville, Tennessee

9:05-9:30 AM

Discussion

9:30-9:45 AM

SPATIAL TRANSCRIPTOMIC ATLAS OF THE HUMAN LUNG IN PAH. Adam J Brownstein^{1}, Brenda Wong¹, Aneta Gandjeva², Gregory Fishbein¹, Rubin Tuder², Jason Hong¹. ¹University of California, Los Angeles; ²University of Colorado Denver School of Medicine, Aurora, CO.*

9:45-10:00 AM

PROTEIN CODING RNA TRANSCRIPTS ASSOCIATED WITH PULMONARY HYPERTENSION IN THE RNA SEQUENCING STUDY FROM THE PVDOMICS COHORT. Gabriele Grunig^{1}, R. Kim¹, E. B. Rosenzweig², J. Leopold³, P. M. Hassoun⁴, S. C. Mathai⁴, C. Simpson⁴, R. Mehra⁵, M. Aldred⁶, B. Borlaug⁷, R. P. Frantz⁷, F. P. Rischard⁸, A. Hemnes⁹, G. J. Beck¹⁰, N. S. Hill¹¹, W.H.W. Tang¹⁰, S. C. Erzurum¹⁰, S. A. Comhair¹⁰, E. Horn¹², W. C. King¹⁰, J. Barnard¹⁰, ¹Med, NYU Grossman School Med, New York, NY; ²Pediatrics, NY Med College, Valhalla, NY; ³Cardiovas Med, Brigham Women's Hosp, Harvard Med School, Boston, MA; ⁴Johns Hopkins Univ School of Med, Baltimore, MD; ⁵U Washington, Seattle, WA; ⁶Indiana U, Indianapolis, IN; ⁷Mayo Clinic, Rochester, MN; ⁸U Arizona, Tucson, AZ; ⁹Vanderbilt U, Nashville, TN; ¹⁰Cleveland Clinic Foundation, Cleveland, OH; ¹¹Tufts Med Ctr, Boston, MA; ¹²Weill Cornell Med Ctr, New York, NY.*

10:00-10:30 AM

.....Coffee Break (Refreshments for conference participants only)

Tuesday, June 9, 2026 -- Morning

Theme 1: Novel Insights in Pulmonary Hypertension Phenotypes and Vascular Remodeling in Pulmonary Circulation-Moderators: Laszlo Farkas, M.D., Troy Stevens, Ph.D., Christine Farrell, M.D.

**10:30-11:05 AM JAN AND PETER HENSON LECTURE
 “ADAPTABLE AND HEMODYNAMIC HUMAN
 ENDOTHELIAL CELLS IN SPECIFYING FUNCTIONAL
 PULMONARY VASCULATURE”**

**Shahin Rafii, M.D.
 Arthur B. Belfer Professor of Genetic Medicine
 Chief, Division of Regenerative Medicine
 Director, Ansary Stem Cell Institute
 Weill Cornell Medicine
 New York, New York**

11:05-11:30 AM Discussion

11:30-11:45 AM A CHIMERIC HUMAN-MOUSE LUNG ENDOTHELIAL MODEL OF PULMONARY VASCULAR DISEASE USING INDUCED PLURIPOTENT STEM CELLS. **Alexander M. Holtz^{1,2*}, Marcus Vorpah^{1,2}, Mohamed J. Ahmed^{2,3}, Eric D. Austin⁴, Pushpinder S. Bawa², Carlos Villacorta-Martin², Darrell N. Kotton^{2,5}, ¹Division of Genetics and Genomics, Boston Children’s Hospital, Boston, MA; ²Center for Regenerative Medicine, Boston University and Boston Medical Center, Boston, MA; ³Hamdan Bin Mohammed College of Dental Medicine, Dubai, UAE; ⁴Department of Pediatrics, Vanderbilt University Medical Center, Monroe Carell Jr. Children’s Hospital, Nashville, TN; ⁵The Pulmonary Center and Department of Medicine, Boston University Chobanian & Avedisian School of Medicine, Boston, MA.**

11:45-12:00 PM SPATIAL ANALYSIS OF VASCULAR NICHES REVEALS A ROLE FOR KIT -- SIGNALING IN PULMONARY HYPERTENSION. **Yuling Deng^{1*}, Shunning Liang¹, Bin Liu¹, Mengcheng Shen², Susan Lin¹, Zhiyu Dai¹, ¹Division of Pulmonary and Critical Care Medicine, Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO; ²Division of Cardiology, Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO.**

12:00-1:30 PM Lunch (lunch not provided by conference)

Tuesday, June 9, 2026 -- Afternoon

**Theme 2: The Vascular Niche in the Pulmonary Circulation: Modifying Resident Cell Function
To Treat Pulmonary Vascular Diseases-Moderators: Zhiyu Dai, Ph.D., Ke Yuan, Ph.D.,
Julia Woodcock, Ph.D.**

1:30-2:05 PM

GILES F. FILLEY LECTURE

**“THERAPEUTIC APPROACHES TO TARGETING ENDOTHELIAL
CELLS AND THEIR PROGENITORS IN THE PULMONARY CIRCULATION”**

Vladimir Kalinichenko, M.D., Ph.D.

Professor and Director

Phoenix Children’s Research Institute

University of Arizona College of Medicine/Phoenix

Phoenix Children’s Hospital

Phoenix, Arizona

2:05-2:30 PM Discussion

2:30-2:45 PM *TOP1 signaling in Pulmonary Arterial Hypertension. Dmitry Goncharov*¹, Lifeng Jiang¹, Iryna Zhyvylo¹, Derek Lin¹, Neil J. Kelly⁴, Lisa Franzl¹, Aisha Saiyed¹, Nicholas J. Kenyon^{1,5}, John R. Greenland^{6,7}, Paul J. Wolters⁶, Stephen Y. Chan^{3,4}, Horace Delisser⁸, Tatiana V. Kudryashova^{3,4}, **Elena A. Goncharova^{1*}**, ¹University of California, Davis School of Medicine, Davis, CA; ²Veterans Affairs Pittsburgh Healthcare System, Pittsburgh, PA; ³Center for Pulmonary Vascular Biology and Medicine, Pittsburgh, Heart, Lung, and Blood Vascular Medicine Institute, University of Pittsburgh, Pittsburgh, PA; ⁴Division of Cardiology, University of Pittsburgh School of Medicine, Pittsburgh, PA; ⁵VA Northern California Healthcare System, Mather, CA; ⁶University of California, San Francisco School of Medicine; ⁷San Francisco Veterans Affairs Health Care System, San Francisco, CA; ⁸University of Pennsylvania Perelman School of Medicine, Philadelphia, PA.*

2:45-3:00 PM *AN EPIGENETIC DEFICIENCY IN ENDOTHELIAL CELLS LEADS TO SPONTANEOUS PULMONARY HYPERTENSION. Van Dung Nguyen¹, **Bisheng Zhou^{1*}**, ¹Department of Pharmacology and Regenerative Medicine, Center for Lung and Vascular Biology, University of Illinois College of Medicine, Chicago, IL.*

3:00-3:30 PMBreak (Refreshments for conference participants only)

Tuesday, June 9, 2026 -- Afternoon

**Theme 2: The Vascular Niche in the Pulmonary Circulation: Modifying Resident Cell Function
To Treat Pulmonary Vascular Diseases-Moderators: Roberto Machado, M.D., Elena
Goncharova, Ph.D., Joseph Hippensteel, M.D.**

3:30-4:05 PM

**MARVIN I. SCHWARZ LECTURE
“*ENDOTHELIUM AS AN ENDOCRINE ORGAN:
THE MULTISYSTEM IMPACT OF THE PULMONARY CIRCULATION
DURING LUNG INJURY AND SEPSIS*”**

***Eric P. Schmidt, M.D.
Chief, Division of Pulmonary and Critical Care Medicine
Associate Professor of Medicine
Harvard Medical Center
Boston, Massachusetts***

4:05-4:30 PM

Discussion

4:30-4:45 PM

*ENDOTHELIAL GLYCOCALYX DESTRUCTION IN SEPSIS IS MEDIATED BY CELL-FREE HEMOGLOBIN-INDUCED UPREGULATION OF LUNG ENDOTHELIAL HEPARANASE. **Lorraine B Ware***, AM Bogart, N Putz, HNR Lee, D Aslaner, KJ Riedmann, JE Meegan, K Oshima, CM Shaver, JA Bastarache, EP Schmidt, JA Bastarache. Dept of Medicine, Vanderbilt University, Nashville TN and Dept of Medicine, Massachusetts General Brigham, Boston, MA,*

4:45-5:00 PM

*Rgs5 DRIVES PERICYTE DIFFERENTIATION AND MICROVASCULAR REMODELING IN PULMONARY HYPERTENSION. Yunhye Kim , Yan Li , **Ke Yuan***, Division of Pulmonary Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA.*

5:00-7:00 PM

POSTER VIEWING (*Refreshments for conference participants only*)

Wednesday, June 10, 2026 -- Morning

Theme 3: The Vascular Niche in the Pulmonary Circulation: Modifying Circulating and Recruited Cell Function to Treat Pulmonary Vascular Diseases-Moderators: Jason Elinoff, M.D., Micheala Aldred, Ph.D., Claudia Mickael, Ph.D.

8:00-8:35 AM

ROGER S. MITCHELL LECTURE

“TARGETING IMMUNE CELL DYSFUNCTION IN THE VASCULAR NICHE OF PULMONARY HYPERTENSION”

Mark R. Nicolls, M.D.

Chief, Division of Pulmonary, Allergy and Critical Care Medicine

Associate Dean for Research

Stanford Professor of Pulmonary and Critical Care Medicine

Stanford University

Palo Alto, California

8:35-9:00 AM

Discussion

9:00-9:15 AM

BMP2 DEFICIENCY-INDUCED TREG DYSREGULATION EXACERBATES THE DEVELOPMENT OF PULMONARY ARTERIAL HYPERTENSION. Dongeon Kim^{1,2*}, Shady Younis^{1,2}, Seunghee Lee^{1,2}, Kyle Song^{1,2}, Evan Bao², Peter Kao¹, Xinguo Jiang², Amy Tian², and Mark Nicolls^{1,2}, ¹Department of Medicine, Stanford University (Stanford, CA); ²Veterans Affairs Palo Alto Health Care System (Palo Alto, CA).

9:15-9:30 AM

SPATIAL AND MOLECULAR PROFILING OF TISSUE-DERIVED SOLUBLE AND MATRIX-BOUND EXTRACELLULAR VESICLES IN PULMONARY HYPERTENSION. Sushil Kumar^{1*}, Ram R. Prasad¹, Hui Zhang¹, Brittany A. McKeon¹, Xinbo Yu¹, Suzette Riddle¹, Christina Coughlan¹, Kirk Hansen¹, Kurt R. Stenmark¹, ¹University of Colorado Anschutz Medical Campus, Aurora, CO.

9:30-10:00 AM

.....Coffee Break (Refreshments for conference participants only)

Wednesday, June 10, 2026 -- Morning

Theme 3: The Vascular Niche in the Pulmonary Circulation: Modifying Circulating and Recruited Cell Function to Treat Pulmonary Vascular Diseases-Moderators: Ralph Schermuly, Ph.D., Cassidy Delaney, M.D., Caitlin Lewis, Ph.D.

10:00-10:35 AM STATE OF THE ART

Craig N. Morrell, D.V.M., Ph.D.

University of Rochester School of Medicine, Rochester, New York

**“Harnessing Interactions Between Platelets and Vascular Wall Cells
in Pulmonary Vascular Diseases”**

10:35-11:00 AM Discussion

11:00-11:15 AM *LET THE CELLS MINGLE: RECIPROCAL INTERCELLULAR CROSSTALK PROTECTS THE PULMONARY VASCULATURE FROM HUMAN IMMUNODEFICIENCY VIRUS-DRIVEN VASCULAR INJURY. Noelia C. Lujera^{1*}, Javaria Baig¹, Amanda K. Garcia¹, Ava G. Oliver¹, Christopher K. Marpa¹, Mario Rodriguez¹, Minh T. Nguyen², Eli Heath³, Isabel Castro-Piedras⁴, Sharilyn Almodovar¹, ¹Department of Immunology & Molecular Microbiology, TTUHSC, Lubbock, Texas; ²Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, Texas; ³Department of Chemical Engineering, Edward E. Whitacre Jr. College of Engineering, Texas Tech University, Lubbock, TX; ⁴Center for Biotechnology and Genomics, Texas Tech University, Lubbock, TX.*

11:15-11:30 AM *MCEMP1 AS A MECHANISTIC BIOMARKER IN PORTOPULMONARY HYPERTENSION. Arun Jose^{1*}, Priyanka Singh¹, Minzhe Guo², Wei Shi¹, ¹Department of Medicine, University of Cincinnati, Cincinnati OH; ²Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati OH.*

12:00-3:00 PM Picnic – T Lazy 7 - The Ranch (for conference participants and their families)

Thursday, June 11, 2026 -- Morning

Theme 4: Understanding Cellular Interactions in the Pulmonary Circulation in Chronic Lung Disease (e.g. COPD, pulmonary fibrosis) and Inhalational Exposures-Moderators: Norbert Weissman, Ph.D., Andrea Frump, Ph.D., Navneet Singh, M.D.

8:00-8:35 AM

**REUBEN M. CHERNIACK LECTURE
“THE PULMONARY CIRCULATION IN COPD, LUNG FIBROSIS
AND ENVIRONMENTAL INHALATIONAL EXPOSURES”**

Grazyna Kwapiszewska, Ph.D.

Professor

LBI for Lung Vascular Research

Medical University of Graz

Graz, Austria

8:35-9:00 AM

Discussion

9:00-9:15 AM

MECHANISM OF ENSIFENTRINE PROTECTION AGAINST ENDOTHELIAL INJURY IN COPD-ASSOCIATED PULMONARY HYPERTENSION. Koichi Nishino^{1*}, Ryen Omesher², Elizabeth Wynn³, Trey Farmer^{3,4}, Steve Groshong⁵, Tim Lahm^{1,6}, Harry Karmouty-Quintana⁷, Rachel Blumhagen⁴, Irina Petrache^{1,6}, ¹Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health; ²Department of Internal Medicine, University of Colorado Anschutz; ³Department of Immunology and Genomic Medicine, National Jewish Health; ⁴Center for Genes, Environment and Health, National Jewish Health; ⁵Division of Pathology, National Jewish Health; ⁶Division of Pulmonology and Critical Care, University of Colorado Anschutz; ⁷Division of Pulmonary, Critical Care, and Sleep Medicine, Department of Internal Medicine, University of Texas Health Science Center at Houston, Houston, TX.

9:15-9:30 AM

VEGFR2 IS ESSENTIAL FOR MICROVASCULAR MAINTENANCE IN THE ADULT LUNG. X.Sun, W.J.He, B.Ahkras, X.Pan, N. Weissmann, A. Vonk Noordergraaf, H.J. Bogaard, Jurjan Aman*, Department of Pulmonary Medicine, PHEniX Lab, Amsterdam University Medical Center, Amsterdam, The Netherlands.

9:30-10:00 AM

.....Coffee Break (Refreshments for conference participants only)

Thursday, June 11, 2026 -- Morning

Theme 4: Understanding Cellular Interactions in the Pulmonary Circulation in Chronic Lung Disease (e.g. COPD, pulmonary fibrosis) and Inhalational Exposures-Moderators: Krithika Lingappan, M.D., David Cornfield, M.D., Betty Phan, M.D.

10:00-10:35 AM

**POLLY E. PARSONS LECTURE
“ENDOTHELIAL CELL MATURATION AND LUNG
VASCULAR INTERACTIONS DURING LUNG DEVELOPMENT”**

Cristina M. Alvira, M.D.
*Benioff UCSF Professor of Pediatrics
Division of Pediatric Critical Care Medicine
Department of Pediatrics
University of California San Francisco
School of Medicine
San Francisco, California*

10:35-11:00 AM Discussion

11:00-11:15 AM

AN EMBRYONIC ARTERY-FORMING NICHE THAT REACTIVATES IN PULMONARY ARTERIAL HYPERTENSION. Wen Tian^{1,2,§,,#}, Timothy Ting-Hsuan Wu^{1,§}, Shenbiao Gu^{1,2,3,§}, Seunghee Lee^{1,2,§}, Hanqiu Zhao⁴, Kyle K. Song^{1,2}, Adam M. Andruska¹, Jason L. Chang^{1,2}, Cerianne Huang^{1,2}, Ryan Vinh^{1,2}, Dongeon Kim^{1,2}, Yu Zhu^{1,2}, Evan Bao^{1,2}, Suti Agarwal¹, Aiqing Cao¹, Junliang Pan^{1,2}, Peter N. Kao¹, Tushar Desai¹, Roham Zamanian¹, Ke Yuan⁵, Lawrence S. Prince¹, Lindsay D. Butcher¹, Roger A. Johns³, Xinguo Jiang^{1,2}, Jason Hong⁶, Marlene Rabinovitch¹, Zhiyu Dai⁴, Kristy Red-Horse¹, Mark R. Nicolls^{1,2,#}, ¹Stanford University School of Medicine, Stanford, California; ²VA Palo Alto Health Care System, Palo Alto California; ³Johns Hopkins University School of Medicine, Baltimore, MD; ⁴Washington University School of Medicine in St. Louis, Saint Louis, MO; ⁵Boston Children's Hospital, Harvard Medical School, Boston, MA; ⁶David Geffen School of Medicine at UCLA, University of California, Los Angeles, CA.*

11:15-11:30 AM

A MEOX2-DEPENDENT MESENCHYMAL NICHE GOVERNS ENDOTHELIAL PATTERNING DURING ALVEOLOGENESIS. Courtney A Stockman, Kimberly Wagner, Thomas J. Taylor, Matthew Riccetti, Jenna Green, Anne-Karina T. Perl, Division of Pulmonary Biology, Cincinnati Children's Hospital Medical Center, Cincinnati, OH.*

11:30-1:30 PMLunch (lunch not provided by conference)

Thursday, June 11, 2026 -- Afternoon

Theme 5: Mechanisms of Cardiac Adaptation and Maladaptation and Their Effects on Heart-Lung Interactions in Pulmonary Vascular Diseases-Moderators-Moderators: Rebecca Vanderpol, Ph.D., Imad Al Ghoulah, Ph.D., Sue Gu, M.D.

1:30-2:05 PM STATE OF THE ART

Ronald J. Vagnozzi, Ph.D.

University of Colorado, Anschutz Medical Campus, Aurora, Colorado

“Emerging Concepts in the Crosstalk Between Cardiac Fibrosis and Immunometabolism and Its Implications for Treating Right Heart Failure”

2:05-2:30 PM Discussion

2:30-2:45 PM *LONGITUDINAL PLASMA PROTEO-METABOLOMICS REVEAL TEMPORALLY CONSISTENT PROCESSES ASSOCIATED WITH PULMONARY ARTERIAL HYPERTENSION. Hongyang Pi^{1*}, Lu Xia²; Samuel G Rayner¹; Ali Shojaie³; Sina A. Gharib¹; Peter J. Leary^{1,4}, ¹University of Washington, Department of Medicine; ²Michigan State University, Department of Statistics and Probability; ³University of Washington, Department of Biostatistics; ⁴University of Washington, Department of Epidemiology, Seattle, WA.*

2:45-3:00 PM *MACHINE LEARNING IDENTIFIES DISTINCT PATTERNS OF RIGHT VENTRICULAR ADAPTATION IN PULMONARY HYPERTENSION. Karina Mora Massad^{1,2*}; Lindsay Forbes²; Kevin Rurak¹; M. Patricia George¹; Darlene Kim¹; Tim Lahm^{1,2,3}, ¹Division of Pulmonary Sciences and Critical Care Medicine, National Jewish Health, Denver, CO; ²University of Colorado Anschutz, Aurora, CO; ³Rocky Mountain Regional VA Medical Center, Aurora, CO.*

3:00-3:30 PMBreak (Refreshments for conference participants only)

Thursday, June 11, 2026 -- Afternoon

Theme 5: Mechanisms of Cardiac Adaptation and Maladaptation and Their Effects on Heart-Lung Interactions in Pulmonary Vascular Diseases-Moderators: Peter Leary, M.D., Ph.D., Larissa Shimoda, Ph.D., Darlene Kim, M.D.

3:30-4:05 PM

THOMAS A. NEFF LECTURE

“THERAPEUTICALLY TARGETING RIGHT HEART REMODELING IN PULMONARY HYPERTENSION”

Corey E. Ventetuolo, M.D., M.S., ATSF

Director, Center for Advanced Lung Care

Brown University

Professor of Medicine, Health Services, Policy & Practice

Alpert Medical School of Brown University

Providence, Rhode Island

4:05-4:30 PM

Discussion

4:30-4:45 PM

*EXERCISE AS THERAPY FOR RIGHT VENTRICULAR DYSFUNCTION IN LUNG DISEASE: PILOT DATA FROM DEPLOYMENT-RELATED RESPIRATORY DISEASE AND CHRONIC OBSTRUCTIVE PULMONARY DISEASE WITH PULMONARY HYPERTENSION. Lindsay M. Forbes^{1,2} *; Justin Cillay¹; Benjamin Sandrin³; Todd M. Bull¹; Amanda Farrell² ; Bree Keller¹; Kelly Moulden¹; Lisa Nicotera¹; Kelly Nielsen¹; Brook Thurman²; Lauren Zell-Baran^{4,5}; Silpa D. Krefft^{1,4,6} ; William K. Cornwell^{2,7}; Tim Lahm^{1,6,8}, ¹Division of Pulmonary, Allergy and Critical Care Medicine, University of Colorado, Aurora, Colorado; ²Clinical Translational Research Center, University of Colorado Anschutz Medical Campus, Aurora, Colorado; ³University of Colorado School of Medicine Anschutz Medical Campus, Aurora, Colorado; ⁴Division of Environmental and Occupational Health Sciences, National Jewish Health, Denver, Colorado; ⁵Department of Epidemiology, Colorado School of Public Health, Aurora, Colorado; ⁶Pulmonary Section, Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, Colorado; ⁷Division of Medicine-Cardiology, University of Colorado, Aurora, Colorado; ⁸Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, Denver, Colorado.*

4:45-5:00 PM

HEMODYNAMIC SHEAR UNMASKS PROTEOSTASIS STRESS PROGRAMS IN PULMONARY ARTERIAL HYPERTENSION ENDOTHELIAL CELLS. Kellen Hirsch¹, ²Christian Mandrycky, ²Isabella Kwan, ²Hongyang Pi, ²William A. Altemeier, ³Tim Lahm, ²Peter J. Leary, ²Sina A. Gharib, ²Ying Zheng, ²Samuel G. Rayner, ¹University of Utah, Department of Medicine, Salt Lake City, UT; ²University of Washington, Department of Medicine, Seattle, WA; ³National Jewish Health, Denver, CO.*

5:00-7:00 PM

POSTER VIEWING (*Refreshments for conference participants only*)

Friday, June 12, 2026 – Morning

Theme 6: Current and Emerging Diagnostic and Treatment Strategies for Pulmonary Hypertension and Pulmonary Vascular Disease-Moderators: Chelsea Magin, Ph.D., Karthik Suresh, M.D., Daniel Colon Hidalgo, M.D.

8:00-8:35 AM STATE OF THE ART

Deepa Gopalan, M.D.

Imperial College London/Cambridge University Hospital, Cambridge, United Kingdom

“Current and Emerging Imaging Methods for the Cardiopulmonary Compartment in COPD, Lung Fibrosis and Pulmonary Hypertension”

8:35-9:00 AM Discussion

9:00-9:15 AM

*QUANTIFYING PULMONARY VASCULAR WALL REMODELING ON CT USING AI-BASED VASCULAR ACTIVITY MAPPING TO ASSESS SERALUTINIB RESPONSE IN PAH. Raúl San José Estépar*¹, Pietro Nardelli¹, Robin Osterhout², Jean-Marie Bruey², Thao Duong-Verle², Richard Aranda², Roham T. Zamanian³, Lawrence S. Zisman², Farbod N. Rahaghi¹, ¹Brigham and Women’s Hospital, Harvard Medical School, Boston, MA; ²Gossamer Bio, Inc., San Diego, CA; ³Stanford University School of Medicine, Stanford Medicine, Stanford, CA.*

9:15-9:30 AM

ENDOSOMAL GTPase RAB7 REGULATES PULMONARY VASCULAR CELL CROSSTALK VIA CSDE1-MEDIATED REGULATION OF THE ENDOTHELIAL SECRETOME. Ganesh Koshre, Daniela Farkas, Liwen Zhang, Elena Goncharova, Rama Mallampalli, Laszlo Farkas, The Ohio State University, Columbus, OH.*

9:30-10:00 AMCoffee Break (Refreshments for conference participants only)

Friday, June 11, 2026 -- Morning

Theme 6: Current and Emerging Diagnostic and Treatment Strategies for Pulmonary Hypertension and Pulmonary Vascular Disease-Moderators: Charly Lai, Ph.D., Ruslan Rafkikov, Ph.D., Clare Prohaska, M.D.

10:00-10:35 AM PARKER B. FRANCIS LECTURESHIP
**“TREATMENT STRATEGIES FOR PULMONARY HYPERTENSION:
INSIGHTS INTO CURRENT AND NOVEL PHARMACOLOGICAL
TARGETS, GENE EDITING, AND CELL THERAPY”**

Paul B. Yu, M.D., Ph.D.

Director, Cardiovascular Research Center

Charles Addison Sanders and Elizabeth Ann Sanders Endowed Chair

Associate Professor of Medicine

Harvard Medical Center

Massachusetts General Hospital

Boston, Massachusetts

10:35-11:00 AM Discussion

11:00-11:15 AM LEPTIN REGULATES PATHWAYS IMPLICATED IN PULMONARY ARTERIAL HYPERTENSION AND SEX-DEPENDENTLY MODULATES PULMONARY VASCULAR TONE. Daniels Konja^{1*}, Keytam S Awad,¹ Shuibang Wang,¹ Colin D Knight,¹ Gabriela A Ferreyra,¹ Kadija Hersi,² Jason M Elinoff,^{1,2} Rebecca Brown,³ Robert L Danner^{1,2}, ¹Critical Care Medicine Department, NIH Clinical Center; ²Critical Care Medicine and Pulmonary Branch, National Heart Lung and Blood Institute (NHLBI); ³National Institute of Diabetes, Digestive and Kidney Diseases (NIDDK), National Institutes of Health, Bethesda, MD.

11:15-11:30 AM IMPAIRED SOX17 EXPRESSION LEADS TO ENDOTHELIAL DYSFUNCTION AND PULMONARY HYPERTENSION BY INSUFFICIENT REPRESSION OF RUNX1. James R. Klinger^{1*}, B. Akosman², E. Vasilaki³, Y. Sharma², M. Pereira², M. J. Choi², E. Y. So², Y. E. Lee², N. Singh¹, C. E. Ventetulo¹, M. R. Wilkins³, L. Zhao³, C. J. Rhodes³, O. D. Liang², ¹Division of Pulmonary, Sleep and Critical Care Medicine; ²Division of Hematology/Oncology, Rhode Island Hospital, Brown University, Providence, RI; ³National Heart and Lung Institute, Imperial College London, London, United Kingdom

11:30-12:30 PM CONFERENCE SUMMARY
Serpil C. Erzurum, M.D.
Executive Vice President
Chief Research and Academic Officer
Alfred Lerner Memorial Chair in
Innovative Biomedical Research Chair
The Cleveland Clinic
Cleveland, Ohio

12:30-1:00 PM Discussion and Adjourn

POSTER VIEWING
Tuesday, June 9, 2026
5:00-7:00 PM

POSTERS

HYPOXIC REPROGRAMMING OF THE LYMPHATIC VASCULAR NICHE DRIVES ALLOIMMUNE INJURY AFTER LUNG TRANSPLANTATION. Seunghye Lee PhD^{1,2}, Kyle K. Song BS^{1,2}, Dongeon Kim PhD^{1,2}, Xinguo Jiang PhD^{1,2}, Amy Tian PhD^{1,2#}, and Mark Nicolls MD^{1,2#} PhD^{1,2#}, and Mark Nicolls MD^{1,2#}, ¹Department of Medicine, Stanford University (Stanford, CA); ²Veterans Affairs Palo Alto Health Care System (Palo Alto, CA).*

ALVEOLAR-CAPILLARY BED FOCUSED MAPPING DEMONSTRATES PROFOUND ENDOTHELIAL IDENTITY REPROGRAMMING AND PROTEOSTATIC IMBALANCE IN ALVEOLAR CAPILLARY DYSPLASIA. Csaba Galambos MD, PhD^{a,b,d}, Gregory R. Keele PhD^c, William Schroeder^{a,b}, R Blair Dodson PhD^c, Steven H. Abman MD^{b,d}, ^aDepartment of Pathology, University of Colorado School of Medicine, Aurora, CO, USA; ^bPediatric Heart Lung Center, Children's Hospital Colorado, Aurora, CO, USA; ^cRTI International, Research Triangle Park, NC, USA; ^dSection of Pediatric Pulmonology, Department of Pediatrics, University of Colorado School of Medicine, Aurora, CO.*

THE ROLE OF ENDOTHELIAL CIRCADIAN RHYTHMS IN RECOVERY FROM PNEUMONIA Reece P. Stevens^{1}, Grant Daly², Isabelle Matoufi¹, Linda Zheng¹, Brianna Banten¹, Sarah Kamali¹, Larissa A. Shimoda¹, and Mahendra Damarla¹ Pulmonary and Critical Care Medicine, Johns Hopkins University, School of Medicine, Baltimore, MD; ¹Department of Pharmacology, University of South Alabama, Mobile, AL.*

MATERNAL AND FETAL OVEREXPRESSION OF LUNG EXTRACELLULAR SUPEROXIDE DISMUTASE (EC-SOD) PROTECTS OFFSPRING LUNG FOLLOWING LATE GESTATIONAL HYPOXIA. Thi-Tina N. Nguyen^{1,3}, Caitlin V. Lewis^{1,3}, Janelle N. Posey^{1,2}, Timothy Porfilio^{1,3}, Cassidy Delaney^{1,2}, Eva S. Nozik^{1,3}, ¹Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO; ²Department of Pediatrics, Division of Neonatology, University of Colorado Anschutz Medical Campus, Aurora, CO; ³Department of Pediatrics, Division of Critical Care, University of Colorado Anschutz Medical Campus, Aurora, CO.*

RNA DEADENYLASE INDUCES ENDOTHELIAL IMMUNOGENIC OXYSTEROLS IN PULMONARY ARTERIAL HYPERTENSION (PAH). Romi Homsy, Jeffrey McDonald, Stephen Chan, Chen-Shan Julia Woodcock, National Jewish Health, Denver, CO.*

PULMONARY CAPILLARY ENDOTHELIAL LOSS OF FOXF1 IS SUFFICIENT TO DRIVE INTERSTITIAL LUNG DISEASE. Jonathan Do^{1†}, Zicheng Deng^{1†}, Wen Gao¹, Ying-Wei Lan¹, Gautam Verma¹, Lance Peter², Nicholas Banovich², Tanya Kalin^{1,3,4}, Vladimir V. Kalinichenko^{1,5}, ¹Phoenix Children's Research Institute, College of Medicine-Phoenix, Phoenix, AZ; ²Division of Bio-Innovation and Genome Sciences, Translational Genomics Research Institute, Phoenix, AZ; ³Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ; ⁴Department of Child Health, Division of Hematology and Oncology, University of Arizona College of Medicine-Phoenix, Phoenix, AZ; ⁵Division of Neonatology, AZ; ⁵Division of Neonatology, Phoenix Children's Hospital, Phoenix, AZ*

POSTERS – Tuesday, June 9, 2026 -continued

INTERMITTENT FASTING MITIGATES PULMONARY HYPERTENSION DUE TO INTERSTITIAL LUNG DISEASE. Benjamin P. Kremer, BS, Elizabeth Ngo, Peter Calabrese, **Sasha Z. Prisco***, Lillehei Heart Institute, Cardiovascular Division, Department of Medicine, University of Minnesota, Minneapolis, MN.

GCN2 ORCHESTRATES LUNG ENDOTHELIAL REPAIR FOLLOWING VIRAL INJURY. **Abhinay Gontu^{1#}**, Ying-Wei Lan^{1#}, Jonathan Do¹, Xiaomei Xia¹, Hasini Chintala¹ and Tanya V Kalin^{1,2}, ¹Phoenix Children's Research Institute, Department of Child Health, College of Medicine, University of Arizona, Phoenix, AZ; ²Center for Cancer and Blood Disorders, Phoenix Children's Hospital, Phoenix, AZ.

VASCULAR-RELATED PROTEOMIC SIGNATURES IN COPD WITH SUSPECTED PULMONARY HYPERTENSION AS PREDICTORS OF FEV₁ IMPAIRMENT. **Khushboo Goel^{1,2,3*}**, Ryen Ormesher^{2,3}, Katherine A. Pratte⁴, Yue Wang⁵, Koichi Nishino², Craig P. Hersh⁶, Katerina Kechris⁵, Russell P. Bowler^{2,7}, Irina Petrache^{2,3}, ¹Department of Medicine, Division of Pulmonary and Critical Care Medicine, Cedars-Sinai Medical Center, Los Angeles, CA; ²Department of Medicine, Division of Pulmonary Critical Care and Sleep Medicine, National Jewish Health, Denver, CO; ³Department of Medicine, Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado, Aurora, CO; ⁴ Department of Biostatistics, National Jewish Health, Denver, CO; ⁵Department of Biostatistics and Informatics, University of Colorado, Aurora, CO; ⁶Department of Medicine, Channing Division of Network Medicine, Brigham and Women's Hospital, Boston, MA; ⁷ Department of Genomic Sciences and Systems Biology, Cleveland Clinic, Cleveland, OH.

ENDOTHELIAL LRRC8 CHANNEL: A NOVEL PROTECTOR AGAINST PULMONARY HYPERTENSION. **Qiujun Yu***, Yonghui Zhao, Rahul Chadda, Nathaniel John, Kel Vin Woo, David Orniz, Zhiyu Dai, Rajan Sah, Department of Internal Medicine, Division of Cardiology (Q.Y., Y.Z., R.C., N.J., R.S.), Division of Pulmonary & Critical Care Medicine (Z.D.); Department of Pediatrics, Division of Cardiology (K.V.W.); Department of Developmental Biology (D.O.), Washington University School of Medicine, Saint Louis, MO.

CARDIOMYOCYTE NLRP3 SIGNALING IN RIGHT HEART FAILURE IS SEXUALLY DIMORPHIC VIA ESTROGEN RECEPTOR α . **Rafael S Fais^{1*}**; Palotta, EDN¹; Kopf, KW¹; Massad, KM^{1,2}; Hoffer, C²; Walts, AD¹; Goldenberg, NM³; Givens, S⁴; Bourgeois, A⁵; Woodcock, CC¹; Petrache I^{1,2}; Chesler, NC⁶; Woulfe, KC²; Pullamsetti SS⁷; Boucherat, O⁵; Provencher, S⁵; Ogle, BM⁴; Bonnet, S⁵, Lahm, T^{1,2,8}, ¹National Jewish Health, Denver, CO; ²University of Colorado Anschutz Medical Campus, Aurora, CO; ³The Hospital for Sick Children, Toronto, Canada; ⁴University of Minnesota Twin Cities, Minneapolis, MN; ⁵Université Laval, Canada; ⁶University of California Irvine, CA; ⁷Max Planck Institute for Heart and Lung Research, Bad Nauheim, Germany; ⁸Rocky Mountain Regional VA Medical Center, Aurora, CO.

LECTIN COMPLEMENT ACTIVATION IS A CRITICAL DRIVER OF SCHISTOSOMA-ASSOCIATED PULMONARY HYPERTENSION. **Claudia Mickael^{1,3*}**, Dara Fonseca-Balladares², Rahul Kumar², Michael H. Lee², Kevin Nolan², Linda Sanders³, Katie Tuscan³, Ramraj Prasad³, Pilar Londono¹, Rubin M. Tuder^{1,3}, Kurt Stenmark³, Brian B. Graham², ¹Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Anschutz Medical Campus, Colorado; ²Department of Medicine, University of California San Francisco, San Francisco, California; ³Cardiovascular Pulmonary Research Lab, University of Colorado School of Medicine, Colorado.

POSTERS – Tuesday, June 9, 2026 -continued

PULMONARY ARTERY ENDOTHELIAL CELL BIOPSIES PROVIDE NEW INSIGHTS INTO ENDOTHELIAL PATHOBIOLOGY IN PULMONARY VASCULAR DISEASE. †**Navneet Singh**^{1,2*}, †**Karina M. Massad**³, Mandy Pereira², Allyson Sherman-Roe², Tiffaney Cayton², Ashley Dennett², Lauren Jackson^{4, 5}, Alexander T. Jorrin², Darlene Kim⁶, James R. Klinger^{1,2}, Christopher J. Mullin^{1,2}, William Oldham^{1,2}, Cameron Patrick², Rachel Sanders², Dhananjay Tambe^{5,7,8}, Elizabeth O. Harrington^{1,9}, Olin D. Liang¹, Troy Stevens^{4,5}, †**Tim Lahm**^{3,6,10}, †**Corey E. Ventetuolo**^{1,2,11}, ¹Dept of Medicine, Alpert School of Medicine at Brown University, Providence, RI; ²Center for Advanced Lung Care, Brown University Health, Providence, RI; ³Dept of Medicine, University of Colorado Anschutz Medical Center, Aurora, CO; ⁴Dept of Physiology and Cell Biology, College of Medicine, University of South Alabama, Mobile, AL; ⁵Center for Lung Biology, College of Medicine, University of South Alabama, Mobile, AL; ⁶Dept of Medicine, National Jewish Health, Denver, CO; ⁷Dept of Pharmacology, College of Medicine, University of South Alabama, Mobile, AL; ⁸Dept of Mechanical Aerospace and Biomedical Engineering, College of Engineering, University of South Alabama, Mobile, AL; ⁹Division of Biology and Medicine, Brown University, Providence, RI; ¹⁰Rocky Mountain Regional Veterans Affairs Medical Center, Aurora, CO; ¹¹Dept of Health Services, Policy and Practice, Brown University, RI; *presenting author, †shared first and senior authorship, respectively

PRECISION-CUT LUNG SLICE CO-CULTURE SYSTEMS FOR EXPLORING MACROPHAGE-ASSOCIATED INFLAMMATION IN PULMONARY HYPERTENSION. **Hui Zhang**^{1*}, B. Alexandre McKeon¹, Ram Raj Prasad¹, Sushil Kumar¹, Suzette Riddle¹, Cheng-jun Hu², Kurt Stenmark¹, ¹Cardiovascular Pulmonary Research Laboratories, Departments of Pediatrics and Medicine, ²Department of Craniofacial Biology, School of Dental Medicine, University of Colorado Anschutz Medical Campus, Aurora, CO.

DISRUPTION OF THE SP-R210L VARIANT OF MYO18Aα IN ALVEOLAR MACROPHAGES RESULTS IN SUBCLINICAL PULMONARY VENO-OCCLUSIVE DISEASE WITH INCREASED RISK FOR DEVELOPMENT OF PULMONARY HYPERTENSION Todd M. Umstead¹, Eric Yau¹, Raz Abdulqadir¹, Kristin K. Fino¹, E Scott Halstead¹, Hannah Atkins¹, Matthew Lanza¹, Han Chen¹, Aymen Halouani², Yassine Sassi², Candace S.Y. Chan¹, Ilias Georgakopoulos-Soares¹, Timothy K Cooper¹, Shaili Amatya¹, **Zisis C. Chroneos**^{1*}, ¹Penn State College of Medicine, Hershey, PA; ²Virginia-Maryland College of Veterinary Medicine, Virginia Tech, Blacksburg, Virginia.

MACHINE LEARNING-BASED PHENOTYPING IN INTERSTITIAL LUNG DISEASE-ASSOCIATED PULMONARY HYPERTENSION: A FEASIBILITY STUDY. **Marcos Fernandes Garcia, MD, PhD**^{1,2*}, Joshua J. Solomon, MD², and Tim Lahm, MD^{1,2,3}, ¹ Division of Pulmonary, Allergy and Critical Care Medicine, University of Colorado; ² Division of Pulmonary, Critical Care and Sleep Medicine, National Jewish Health, ³ Denver, Colorado; Rocky Mountain Regional VA Medical Center, Aurora, CO.

LATENT FACTOR ANALYSIS REVEALS DYNAMIC FIBROBLAST STATE TRANSITIONS DURING HYPOXIA-INDUCED RV REMODELING. Vitaly Kheyfets¹, Alyse Staley², Claudia Mickael^{1,3}, Linda Sanders^{1,3}, Kurt R Stenmark¹, **Sue Gu**^{1,3*}, ¹Pediatric Critical Care Medicine; Developmental Lung Biology and CVP Research Laboratories, School of Medicine, University of Colorado Anschutz, Aurora, CO; ²University of Colorado Anschutz Cancer Center Bioinformatics Core Facility; ³Division of Pulmonary, Allergy, and Critical Care, Department of Medicine, University of Colorado Anschutz, Aurora, CO.

POSTERS – Tuesday, June 9, 2026 -continued

*TARGETING XPB DEGRADATION WITH SPIRONOLACTONE ANALOGS REVEALS A NOVEL THERAPEUTIC STRATEGY FOR INFLAMMATION. **Li-Yuan Chen**^{1*}, Venkatareddy R. Sabbasani², Yi-Han Lin³, Scott Wilson¹, Edward J. Dougherty⁵, Rolf Swenson², Juan Marugan³, Mark Henderson³, Ken Cheng⁴, Robert L. Danner⁵ and Jason M. Elinoff^{1,5*}, ¹Critical Care Medicine and Pulmonary Branch and ²Chemistry and Synthesis Center, National Heart, Lung, and Blood Institute, Bethesda, MD; ³Early Translation Branch, Division of Preclinical Innovation and ⁴Functional Genomics Laboratory, National Center for Advancing Translational Sciences, Rockville, MD; ⁵Critical Care Medicine Department, NIH Clinical Center, Bethesda, MD.*

*INTERIM ANALYSIS OF ARTISAN: MPAP REDUCTION AND RIGHT VENTRICLE FUNCTION IMPROVEMENTS WITH EARLY TREPROSTINIL THERAPY IN PULMONARY ARTERIAL HYPERTENSION. **Raymond Benza**^{1*}, K Chin², D Lachant³, C Miller⁴, R Naeije⁵, A Waxman⁶, J White³, R Zolty⁷, N Daczkowski⁸, G Golden⁸, K Paxton⁸, F Rahaghi⁸, Y Liu⁸, H Matsubara⁹, ¹Sentara Health, Norfolk, USA, ²UT Southwestern Medical Center, Dallas, USA, ³University of Rochester Medical Center, Rochester, USA, ⁴Piedmont Healthcare, Atlanta, USA, ⁵Free University of Brussels, Brussels, Belgium, ⁶Brigham and Woman's Hospital, Boston, USA, ⁷University of Nebraska College of Medicine, Omaha, USA, ⁸United Therapeutics Corporation, Research Triangle Park, USA, ⁹NHO Okayama Medical Center, Okayama, Japan. This is an encore, previously presented at PVRI in January 2026.*

*THE ARTERIAL-TO-LUNG SIZE-RATIO (ARTLR) PAIRED WITH AIRWAY DYSANAPSIS CORRELATES WITH COPD-ASSOCIATED CT BIOMARKERS. **Soheil Hosseini**^{1*}, Z Yang¹, SE Gerard¹, BM Smith², EA Hermann³, AP Comellas¹, S Fortis¹, JM Reinhardt¹, JL Curtis⁴, PG Woodruff⁵, NN Hansel⁶, RG Barr³, MK Han⁴, EA Hoffman¹ for the SPIROMICS investigators, for the SPIROMICS investigators, ¹University of Iowa, ²McGill University, ³Columbia University, ⁴University of Michigan, ⁵University of California San Francisco, ⁶Johns Hopkins University.*

POSTER VIEWING
Thursday, June 11, 2026
5:00-7:00 PM

POSTERS

REPROGRAMMED LYVE1⁺ MACROPHAGES PROMOTE PULMONARY HYPERTENSION. Caitlin Lewis^{1}, Thi-Tina Nguyen¹, Janelle Posey¹, Mariah Jordan¹, Nathan Dee¹, Timothy Porfilio¹, Amelia Rosin¹, C Michael Hart², Harry Karmouty-Quintana³, Cassidy Delaney¹, Eva Nozik¹, ¹Sections of Pediatric Critical Care Medicine and Neonatology, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora CO, ²Division of Pulmonary, Allergy, Critical Care, and Sleep Medicine, Emory University Atlanta, GA, ³Divisions of Critical Care, Pulmonary & Sleep Medicine, McGovern Medical School, University of Texas Health Science Center, Houston, TX.*

*SOX17 DRIVES RESILIENCE OF THE ARTERIAL ENDOTHELIUM UNDER SHEAR STRESS. B.F. Neep, L.E. de Heus, L.Raaz, X.Sun, X.Pan, F. van Leeuwen, R.Szulcek, C. Dickhoff, J.Jatzlau, P.Knaus, A.van der Meer, F.de Man, C.Rhodes, MR.Wilkins, A.Vonk Noordegraaf, M.J.Goumans, H.J.Bogaard, **Jurjan Aman***, Department of Pulmonary Medicine, PHEniX Lab, Amsterdam University Medical Center, Amsterdam, The Netherlands.*

*A SINGLE-CELL AND SPATIAL TRANSCRIPTOMIC ATLAS OF HUMAN PULMONARY ARTERIAL HYPERTENSION. Hanqiu Zhao, Shunning Liang, Bin Liu, **Zhiyu Dai***, Division of Pulmonary and Critical Care Medicine, Department of Medicine, School of Medicine, Washington University in St. Louis, St. Louis, MO.*

PRECLINICAL MODELS SUPPORT THE SYNERGISTIC POTENTIAL OF SERALUTINIB AND SOTATERCEPT IN TREATING PULMONARY ARTERIAL HYPERTENSION (PAH). Ravikumar Sitapara^{1}, Eduardo Garcia¹, Robin Osterhout¹, Zhaoqing Ding¹, Lawrence S. Zisman¹, Thao Duong-Verlé¹, Robert F. Roscigno¹, Richard Aranda¹, Marc Humbert^{2,3}, Ly Tu^{2,3}, Christophe Guignabert^{2,3}, Jean-Marie Bruey¹, ¹Gossamer Bio, Inc., San Diego, CA, USA; ²Université Paris-Saclay, Hypertension Pulmonaire: Physiopathologie and Innovation Thérapeutique, HPPIT, Faculté de Médecine, Le Kremlin-Bicêtre, France; ³INSERM UMR_S 999, HPPIT, Le Kremlin-Bicêtre, France.*

MODULATION OF ENDOTHELIAL-TRANSDIFFERENTIATION IN PULMONARY HYPERTENSION: ROLE FOR EBP50 AND MICROBIOME-DERIVED METABOLITES. Andres Pulgarin-Rocha^{1,2}, Anastasia Gorelova³, and Imad Al Ghouleh^{1,2}, ¹Brown University Health /Department of Medicine Brown University, Providence, RI; ²Providence VA Medical Center, Providence, RI; ³University of Pittsburgh Medical Center, Pittsburgh, PA.*

HYPOXIA-INDUCED PLATELET ACTIVATION, BUT NOT HYPOXIA-INDUCED PULMONARY HYPERTENSION, IS IFNR COPY-INDEPENDENT IN THE DP16 MOUSE MODEL OF DOWN SYNDROME (TRISOMY 21). Janelle N. Posey^{1,8}, Mariah Jordan^{1,8}, Thi-Tina N. Nguyen^{3,6}, Christine Farrell^{2,7}, Caitlin V. Lewis^{3,8}, Daniel Colon-Hidalgo^{2,7}, Eva S. Nozik^{3,8}, Kelly D. Sullivan^{4,6}, Joaquin M. Espinosa^{5,6}, Cassidy Delaney^{1,8}, ¹Section of Neonatology; ²Division of Pulmonary Sciences and Critical Care Medicine; ³Pediatric Critical Care Medicine; ⁴Section of Developmental Biology; ⁵Department of Pharmacology; ⁶Linda Crnic Institute for Down Syndrome; ⁷Department of Medicine; ⁸Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO.*

POSTERS – Thursday, June 11, 2026 -continued

*HIPK2/E2F2 AXIS SUPPORTS INCREASED PROLIFERATION OF PULMONARY ARTERIAL SMOOTH MUSCLE CELLS IN PULMONARY ARTERIAL HYPERTENSION. Andressa Pena¹, Theodore Avolio¹, Lifeng Jiang², Dmitry Goncharov², Horace DeLisser³, Elena A Goncharova², **Tatiana V Kudryashova^{1*}**, ¹University of Pittsburgh, Pittsburgh, PA; ²University of California, Davis, Davis, CA; ³University of Pennsylvania, Philadelphia, PA.*

*ADVENTITIAL FIBROBLAST DERIVED COMPLEMENT FACTOR D PROMOTES INFLAMMATION AND IMMUNE CELL CROSSTALK IN PULMONARY HYPERTENSION. **Ram Raj Prasad***, S. Kumar, H. Zhang, H. Cheng-Jun, M. Li, S. Riddle, B. A. McKeon, K. R. Stenmark, CVP School of Medicine, Aurora, CO.*

*METABOLIC DYSREGULATION DRIVES PLATELET ACTIVATION AND SICKLE CELL DISEASE-ASSOCIATED PULMONARY HYPERTENSION. **Daniel Colon Hidalgo***, Nathan Dee, Christina Lisk, Delaney Swindle, Melissa Lucero, Janelle Posey, Caitlin Lewis, Christina Sul, Cassidy Delaney, David Irwin, Eva Nozik, University of Colorado, Anschutz Medical Campus, Aurora, CO.*

*IS HEPATOSPLENIC SCHISTOSOMIASIS A PRE-PAH PHENOTYPE? INSIGHTS FROM INVASIVE EXERCISE HEMODYNAMICS. **Fernanda P Oliveira^{1,2*}**, Thaís C F Menezes¹, Juliana L Santos¹, Ana Carolina B Duarte¹, Gabriela OS Costa¹, Priscila A Sperandio¹, Jaqueline S Ota-Arakaki¹, Eloara VM Ferreira¹, Claudia Mickael², Rudolf KF Oliveira¹, ¹Division of Respiratory Diseases, Department of Medicine, Hospital São Paulo, Federal University of São Paulo (UNIFESP), São Paulo, SP, Brazil; ²Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, University of Colorado Denver/Anschutz Medical Campus, Aurora, CO, United States.*

*EBF1 SPECIFIES AN ENDOTHELIAL NICHE THAT DRIVES PULMONARY ARTERIAL DEVELOPMENT. **Seunghye Lee^{1,2*}**, Kyle K. Song^{1,2}, Dongeon Kim^{1,2}, Xinguo Jiang^{1,2}, Amy Tian^{1,2#}, Mark Nicolls^{1,2#}, ¹Department of Medicine, Stanford University (Stanford, CA); ²Veterans Affairs Palo Alto Health Care System (Palo Alto, CA). # Co-mentors.*

*C3aR IS ESSENTIAL FOR THE DEVELOPMENT OF HYPOXIA INDUCED PULMONARY HYPERTENSION. **Christine L Farrell^{1*}**, Janelle N Posey², Caitlin V Lewis³, Mariah Jordan², Eva S Nozik³, Cassidy A Delaney², ¹Division of Pulmonary Sciences and Critical Care Medicine, Department of Medicine, ²Section of Neonatology, ³Section of Pediatric Critical Care Medicine, Department of Pediatrics, University of Colorado Anschutz Medical Campus, Aurora, CO.*

*EFFECTS OF NERANDOMILAST ON BIOMARKERS OF VASCULAR DAMAGE IN PATIENTS WITH IDIOPATHIC PULMONARY FIBROSIS (IPF). **Francesco Bonella^{1*}**, Justin M Oldham,² Arata Azuma,^{3,4} Klaus B Rohr,⁵ Nichiren Pillai,⁵ Wibke Stansen,⁶ Carina Itrich,⁷ Christian Hesslinger,⁷ Toby M Maher^{8,9}, ¹Center for Interstitial and Rare Lung Diseases, Pneumology Department, University Hospital Essen, Ruhrlandklinik, Essen, Germany; ²Pulmonary and Critical Care Medicine, University of Michigan, Ann Arbor, Michigan, USA; ³Clinical Research Center, Mihara General Hospital, Saitama, Japan; ⁴Nippon Medical School, Tokyo, Japan; ⁵Boehringer Ingelheim International GmbH, Ingelheim, Germany; ⁶Boehringer Ingelheim Pharma GmbH & Co. KG, Ingelheim, Germany; ⁷Boehringer Ingelheim Pharma GmbH & Co. KG, Biberach, Germany; ⁸Department of Pulmonary, Critical Care and Sleep Medicine, Keck School of Medicine, University of Southern California, Los Angeles, CA, USA; ⁹National Heart and Lung Institute, Imperial College London, London, UK.*

POSTERS – Thursday, June 11, 2026 -continued

A CYTOSKELETAL MASTER SWITCH THAT ORCHESTRATES PATHOLOGIC VASCULAR REMODELING IN PULMONARY ARTERIAL HYPERTENSION (PAH). **Keytam S. Awad^{1*}**, Shuibang Wang¹, Daniels Konja¹, Gabriela A. Ferreyra¹, Christina Zhu¹, Jason M. Elinoff^{1,2}, Robert L. Danner^{1,2}, ¹Critical Care Medicine Department, NIH Clinical Center; ²Critical Care Medicine and Pulmonary Branch, National Heart Lung and Blood Institute, NIH, Bethesda, MD.

β-ARRESTIN 1 DEFICIENCY SENSITIZES PULMONARY HYPERTENSION SMOOTH MUSCLE CELLS (PASMCs) TO BLUE LIGHT-INDUCED APOPTOSIS. **Xin Yun***, Gautam Sikka, Ara Schrems, Yingze Martin Ma, Hermella Demisie, Haiyang Jiang, Nicolas Philip, Larissa A. Shimoda Johns Hopkins School of Medicine, Baltimore, MD.

EFFECT OF HIF-1 ACTIVATION ON P38-MAP KINASE PATHWAY ACTIVATION IN PULMONARY ARTERIAL SMOOTH MUSCLE CELLS (PASMC). **Michael Koenig***, Xin Yun, Haiyang Jiang, Manuella Ribas Andradre, Mahendra Damarla, Larissa Shimoda. Johns Hopkins University (Division of Pulmonary and Critical Care Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland, United States.

PATIENT REPORTED OUTCOMES IN INTERSTITIAL LUNG DISEASE WITH AND WITHOUT PULMONARY HYPERTENSION: INTERIM RESULTS FROM THE PHINDER STUDY. S.D. Nathan¹, M. DerSarkissian², D. Kiely³, T. Kulkarni⁴, S. Sahay⁵, M. Broderick⁶, D. Lee⁶, K. Maher⁶, **Claire M. Thrasher^{6*}**, M.B. Scholand⁷, D. Zisman⁸, O.A. Shlobin¹, ¹Inova Fairfax Hospital, Falls Church, VA; ²Analysis Group, Los Angeles, CA; ³University of Sheffield, Sheffield, UK; ⁴University of Alabama, Birmingham, AL; ⁵Houston Methodist Hospital, Houston, TX; ⁶United Therapeutics, Research Triangle Park, NC; ⁷University of Utah, Salt Lake City, UT; ⁸Cleveland Clinic Florida, Weston, FL.

AKT-DEPENDENT VPS34 ACTIVATION IN PULMONARY ARTERIAL HYPERTENSION Anthony Natoli¹, Kaylin Piza-Taylor¹, Benjamin Reinhard^{1,2}, Felix Aung¹, Logan Hallee³, Jason P. Gleghorn^{3,4}, **Yuanjun Shen^{1*}**, ¹School of Pharmacy and Pharmaceutical Science, Binghamton University, NY; ²Harpur College of Arts and Sciences, Binghamton University, NY; ³Center for Bioinformatics and Computational Biology, University of Delaware, DE; ⁴Department of Biomedical Engineering, University of Delaware, DE.

PULMONARY VASODILATION WITH TREPROSTINIL PALMITIL (TP) INHALATION POWDER (TPIP) IN RAT ISOLATED PERFUSED LUNGS. **Tam Nguyen***, Christina Chang, David Cipolla, Mary Kelly, Zhili Li, Vladimir Malinin, Walter Perkins, Veronica Viramontes, Junguo Zhou, Michel Corboz, Insmmed Incorporated, Bridgewater, NJ.

UNEXPECTED POTENTIALLY HARMFUL EFFECT OF THE SODIUM GLUCOSE COTRANSPORTER TYPE 2 INHIBITOR DAPAGLIFLOZIN IN A MOUSE MODEL OF COPD-ASSOCIATED PULMONARY HYPERTENSION. **Seyedali Mousavi Aghdas^{1*}**, Katrina Kopf¹, Joanna Poczobutt¹, Tsering Palmo¹, Lennart Jost¹, Koichi Nishino¹, Tanner Rivera¹, Tim Lahm^{1,2}, Irina Petrache^{1,2}, ¹Division of Pulmonary, Critical Care, and Sleep Medicine, National Jewish Health; ²Division of Pulmonary Sciences and Critical Care Medicine, University of Colorado Anschutz, Aurora, CO.